Reuters logo
Catalyst Pharma's neuromuscular drug succeeds in study
2017年3月15日 / 中午12点28分 / 6 个月前

Catalyst Pharma's neuromuscular drug succeeds in study

March 15 (Reuters) - Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

The drug, Firdapse, was being tested on seven patients with Musk-MG, a rare subpopulation of MG patients. There are currently no FDA approved therapies for this form of MG.

Catalyst’s shares jumped about 20 percent to $1.40 before the bell on Wednesday. (Reporting by Divya Grover in Bengaluru; Editing by Savio D‘Souza)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below